Case Report of Probable DRESS Syndrome Associated with Ribociclib.

IF 0.6 Q4 ONCOLOGY
Case Reports in Oncological Medicine Pub Date : 2023-11-23 eCollection Date: 2023-01-01 DOI:10.1155/2023/7904950
Florian Carneiro, Marine Bove, Frédérique Beau-Salinas, Tevy San, Pierre Combe
{"title":"Case Report of Probable DRESS Syndrome Associated with Ribociclib.","authors":"Florian Carneiro, Marine Bove, Frédérique Beau-Salinas, Tevy San, Pierre Combe","doi":"10.1155/2023/7904950","DOIUrl":null,"url":null,"abstract":"<p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis. The RegiSCAR score was 4. The symptomatology evolved favorably with topical and systemic corticosteroids, without any sequel. Another CDK4/6 inhibitor, palbociclib, was introduced later without any cross-toxicity and with an excellent therapeutic response for more than 3 years.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689064/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/7904950","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis. The RegiSCAR score was 4. The symptomatology evolved favorably with topical and systemic corticosteroids, without any sequel. Another CDK4/6 inhibitor, palbociclib, was introduced later without any cross-toxicity and with an excellent therapeutic response for more than 3 years.

可能与利博西尼相关的DRESS综合征病例报告。
药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)是一种罕见但已知且可能严重的药物副作用。最近开发的细胞周期蛋白依赖性激酶4/6 (CDK4/6)抑制剂,如ribociclib,已经大大改善了激素受体阳性(HR+)和HER2阴性(HER2-)晚期乳腺癌的管理。在这里,我们报告了一例83岁的患者,他发展为可能由核糖素引起的DRESS综合征,表现为发烧、嗜酸性粒细胞增多、皮疹和肝细胞溶解。RegiSCAR评分为4分。局部和全身皮质类固醇的症状发展良好,没有任何后遗症。另一种CDK4/6抑制剂palbociclib后来被引入,没有任何交叉毒性,并且在3年多的时间里有很好的治疗反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
11
审稿时长
16 weeks
期刊介绍: Case Reports in Oncological Medicine is a peer-reviewed, Open Access journal that publishes case reports and case series related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信